- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04198766
Studio di INBRX-106 e INBRX-106 in combinazione con Pembrolizumab in soggetti con tumori solidi localmente avanzati o metastatici (agonista esavalente OX40)
Uno studio di fase 1 in aperto, multicentrico, first-in-human, dose-escalation, di INBRX-106 e INBRX-106 in combinazione con pembrolizumab in soggetti con tumori solidi localmente avanzati o metastatici
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
- Droga: INBRX-106 - Hexavalent OX40 agonist antibody
- Droga: pembrolizumab 200 mg
- Droga: pembrolizumab 400 mg
- Droga: Carboplatin AUC-5
- Droga: Pemetrexed 500 mg/m2
- Droga: Cisplatin 75mg/m2
- Droga: Carboplatin AUC-6
- Droga: Paclitaxel 200mg/m2
- Droga: Nab paclitaxel 100mg/m2
- Droga: Gemcitabine (1000 mg/m2)
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Study Director - Inhibrx Biosciences, Inc
- Numero di telefono: 858-500-7833
- Email: clinicaltrials@inhibrx.com
Luoghi di studio
-
-
-
Busan, Corea del Sud
- Non ancora reclutamento
- Inje University College of Medicine
-
Investigatore principale:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, Corea del Sud
- Non ancora reclutamento
- Chungbuk National University Hospital
-
Investigatore principale:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, Corea del Sud
- Reclutamento
- The Catholic University of Korea, St. Vincent's Hospital
-
Investigatore principale:
- Byoung Yong Shim
-
Hwasun, Corea del Sud
- Non ancora reclutamento
- Chonnam National University Hwasun Hospital
-
Investigatore principale:
- In-Jae Oh, MD, MS, PhD
-
Incheon, Corea del Sud
- Non ancora reclutamento
- Gachon University Gil Medical Center
-
Investigatore principale:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, Corea del Sud
- Non ancora reclutamento
- CHA Bundang Medical Center
-
Investigatore principale:
- Yoon Beom Sang
-
Seoul, Corea del Sud
- Reclutamento
- Asan Medical Center
-
Contatto:
- Bokyeong Jung, RN
- Email: bokyeong_jung@amc.seoul.kr
-
Investigatore principale:
- Dae Ho Lee, MD
-
Seoul, Corea del Sud
- Reclutamento
- Severance Hospital, Yonsei University Health System
-
Contatto:
- Miyeon Lee
- Email: lee_my@yuhs.ac
-
Investigatore principale:
- Sun Mun Lim
-
Seoul, Corea del Sud
- Reclutamento
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
Investigatore principale:
- SookHee Hong
-
Contatto:
- Na Ayn
- Email: Ahnna331@gmail.com
-
Seoul, Corea del Sud
- Non ancora reclutamento
- Korea University Anam Hospital
-
Investigatore principale:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, Corea del Sud
- Non ancora reclutamento
- Hanyang University Seoul Hospital
-
Investigatore principale:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, Corea del Sud
- Non ancora reclutamento
- Korea University Guro Hospital
-
Investigatore principale:
- Sung Yong Lee
-
Investigatore principale:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, Corea del Sud
- Non ancora reclutamento
- Ajou University Hospital
-
Investigatore principale:
- Yong-Won Choi, MD
-
-
-
-
-
Singapore, Singapore
- Completato
- Curie Oncology
-
Singapore, Singapore
- Completato
- Icon Cancer Centre Farrer Park
-
Singapore, Singapore
- Completato
- Icon Cancer Centre Mount Alvernia
-
-
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Attivo, non reclutante
- City of Hope
-
Glendale, California, Stati Uniti, 91204
- Reclutamento
- Oncura Health
-
Contatto:
- Elizabeth Brown
- Email: Elizabeth.Brown@lahomg.com
-
Investigatore principale:
- Sungwon Kyung, MD
-
La Jolla, California, Stati Uniti, 92037
- Non ancora reclutamento
- UC San Diego Health - Moores Cancer Center
-
Investigatore principale:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, Stati Uniti, 90027
- Reclutamento
- California Research Institute
-
Investigatore principale:
- Ghassan Al-Jazayrly, MD
-
Contatto:
- Swati Shrestha
- Email: sw@caresinst.com
-
Los Angeles, California, Stati Uniti, 90069
- Reclutamento
- Valkyrie Clinical Trials
-
Investigatore principale:
- David Berz, MD
-
Contatto:
- Myo Zaw
- Email: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, Stati Uniti, 90033
- Non ancora reclutamento
- University of Southern California Norris Comprehensive Cancer Center
-
Investigatore principale:
- Jorge Nieva, MD
-
Murrieta, California, Stati Uniti, 92562
- Reclutamento
- Valkyrie Clinical Trials
-
Investigatore principale:
- David Berz, MD
-
Contatto:
- Isabella Gudino
- Email: Isabella.gudino@vctcare.com
-
Santa Rosa, California, Stati Uniti, 95403
- Reclutamento
- Providence Medical Foundation
-
Investigatore principale:
- Ian Anderson, MD
-
Contatto:
- Clinical Research Coordinator
- Numero di telefono: 1181 707-521-3810
- Email: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, Stati Uniti, 80228
- Non ancora reclutamento
- Valkyrie Clinical Trials - Colorado
-
Investigatore principale:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, Stati Uniti, 34711
- Reclutamento
- Clermont Oncology Center
-
Investigatore principale:
- Gopal Kunta, MD
-
Contatto:
- Kiran Penta
- Email: kiran@aorcorp.com
-
Orange City, Florida, Stati Uniti, 32763
- Reclutamento
- Mid Florida Hematology and Oncology Center
-
Investigatore principale:
- Santosh Nair, MD
-
Contatto:
- Kiran Penta
- Email: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Attivo, non reclutante
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Non ancora reclutamento
- University of Illinois Cancer Center
-
Investigatore principale:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, Stati Uniti, 60637
- Attivo, non reclutante
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa
-
Investigatore principale:
- Douglas Laux, MD
-
Contatto:
- Jordan Harrelson
- Numero di telefono: 319-467-5831
- Email: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40202
- Reclutamento
- Norton Cancer Institute
-
Investigatore principale:
- John Hamm, MD
-
Contatto:
- Jenn Broadway, RN
- Numero di telefono: 19535 502-629-2500
- Email: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Henry Ford Cancer Institute
-
Investigatore principale:
- Amy Weise, MD
-
Contatto:
- Mahmoud Hossami
- Numero di telefono: 313-725-7842
- Email: mhossam1@hfhs.org
-
Detroit, Michigan, Stati Uniti, 48201
- Completato
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, Stati Uniti, 49546
- Attivo, non reclutante
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, Stati Uniti, 55426
- Attivo, non reclutante
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Completato
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Non ancora reclutamento
- Washington University in St. Louis School of Medicine
-
Investigatore principale:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, Stati Uniti, 59102
- Completato
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, Stati Uniti, 68803
- Non ancora reclutamento
- Nebraska Cancer Specialists - Grand Island
-
Investigatore principale:
- Ralph Hauke, MD
-
Omaha, Nebraska, Stati Uniti, 68130
- Reclutamento
- Nebraska Cancer Specialists
-
Investigatore principale:
- Ralph Hauke, MD
-
Contatto:
- Lindsey Becker
- Numero di telefono: 402-691-5255
- Email: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Non ancora reclutamento
- MD Anderson Cancer Center at Cooper
-
Investigatore principale:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, Stati Uniti, 10467
- Attivo, non reclutante
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Attivo, non reclutante
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Attivo, non reclutante
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Non ancora reclutamento
- Lehigh Valley Health Network
-
Investigatore principale:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37923
- Non ancora reclutamento
- University of Tennessee Health Science Center
-
Investigatore principale:
- Sean Jordan, MD
-
Nashville, Tennessee, Stati Uniti, 37204
- Attivo, non reclutante
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75230
- Completato
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, Stati Uniti, 79915
- Completato
- Renovatio Clinical - El Paso
-
San Antonio, Texas, Stati Uniti, 78229
- Completato
- NEXT Oncology
-
The Woodlands, Texas, Stati Uniti, 77380
- Completato
- Renovatio Clinical
-
Tyler, Texas, Stati Uniti, 75701
- Reclutamento
- The University of Texas Health Science Center at Tyler
-
Contatto:
- Chaney Story
- Email: Chaney.Story@uttyler.edu
-
Investigatore principale:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Completato
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Froedtert Hospital and the Medical College of Wisconsin
-
Investigatore principale:
- Jonathan Thompson, MD
-
Contatto:
- Ellen Smith
- Email: eksmith@mcw.edu
-
-
-
-
-
Changhua, Taiwan
- Attivo, non reclutante
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, Taiwan
- Attivo, non reclutante
- E-Da Cancer Hospital
-
Kaohsiung City, Taiwan
- Attivo, non reclutante
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, Taiwan
- Attivo, non reclutante
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- Completato
- Taipei Veterans General Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Sperimentale: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
|
|
Sperimentale: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
|
|
Sperimentale: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
|
|
Sperimentale: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Altri nomi:
|
|
Sperimentale: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Altri nomi:
|
|
Comparatore attivo: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Sperimentale: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Sperimentale: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
|
|
Sperimentale: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
|
|
Sperimentale: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Altri nomi:
|
|
Sperimentale: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Altri nomi:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
Sperimentale: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
Sperimentale: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
|
|
Sperimentale: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Altri nomi:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Altri nomi:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Lasso di tempo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Lasso di tempo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Lasso di tempo: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Lasso di tempo: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Lasso di tempo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Lasso di tempo: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
Lasso di tempo: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
Lasso di tempo: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
Lasso di tempo: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
Lasso di tempo: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
Lasso di tempo: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Lasso di tempo: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Lasso di tempo: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Clinical Lead, Inhibrx Biosciences, Inc
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Cancro testa e collo
- Cancro ai polmoni
- NSCLC
- Carcinoma polmonare non a piccole cellule
- Carcinoma
- Neoplasie
- Immunoterapia
- Pembrolizumab
- Chemioterapia
- Chiavetruda
- HNSCC
- Neoadiuvante
- Agenti antineoplastici
- Adiuvante
- Tumori solidi
- Cancro orale
- Cancro orofaringeo
- INBRX-106
- Agenti antineoplastici, immunologici
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie per tipo istologico
- Neoplasie per sede
- Carcinoma a cellule squamose della testa e del collo
- Meccanismi molecolari dell'azione farmacologica
- PD-L1 positivo
- Neoplasie, cellule squamose
- Carcinoma, cellule squamose
- Cancro ipofaringeo
- Fase 1 e Fase 2
- Sperimentazione clinica di fase 1 e fase 2
- Agonista del recettore OX40
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie della bocca
- Malattie stomatognatiche
- Neoplasie urogenitali
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie delle vie respiratorie
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Malattie polmonari
- Adenocarcinoma
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Malattie della pelle
- Neoplasie urologiche
- Malattie otorinolaringoiatriche
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Neoplasie renali
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Tumori neuroendocrini
- Neoplasie faringee
- Neoplasie otorinolaringoiatriche
- Malattie faringee
- Nevi e melanomi
- Neoplasie cutanee
- Malattie della pelle e del tessuto connettivo
- Carcinoma a cellule squamose della testa e del collo
- Neoplasie
- Neoplasie allo stomaco
- Carcinoma
- Neoplasie polmonari
- Carcinoma, cellule squamose
- Carcinoma, cellule renali
- Carcinoma, polmone non a piccole cellule
- Neoplasie della testa e del collo
- Melanoma
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie, cellule squamose
- Neoplasie della bocca
- Carcinoma, cellula di transizione
- Neoplasie orofaringee
- Neoplasie per sede
- Neoplasie ipofaringee
- Aminoacidi, peptidi e proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Guanina
- Ipossantine
- Purinoni
- Purine
- Glutammati
- Aminoacidi, acido
- Aminoacidi
- Aminoacidi, dicarbossilico
- Taxoidi
- Ciclodecani
- Diterpenes
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Economia e organizzazioni sanitarie
- Composti di platino
- Economia
- Pemetrexed
- Gemcitabina
- Paclitaxel
- Cisplatino
- pembrolizumab
- Tasse
Altri numeri di identificazione dello studio
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (Altro identificatore: Merck Sharp & Dohme LLC)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .